N6-Methyladenosine in the Heart
N6-Methyladenosine in the Heart
复制标题
DOI：
10.1007/978-3-030-71612-7_11
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
V. Kmietczyk;Ellen Malovrh;M. Völkers
中科院分区：
文献类型：
--
作者：
V. Kmietczyk;Ellen Malovrh;M. Völkers
与DNA修饰类似，在过去的几年里，心血管系统中出现了一种mRNA修饰的表位转录组。具体地说，N6-甲基腺苷(M6A)作为mRNAs可逆转录后修饰的发现，最近引起了人们对心肌细胞中的这些修饰及其在疾病心脏中的作用的兴趣。由于不同基因的mRNA水平并不一定对应于各自的蛋白质水平，转录后mRNA修饰已被认为是心肌细胞基因表达的相关机制。因此，人类心脏组织和动物模型心脏样本中的m6A-mRNA甲基组被报道，并指出m6A修饰在心肌细胞功能中的重要作用。显然，需要更多的研究来充分了解心脏中维持正常心脏功能的这种新的应激反应机制。在本章中，我们回顾了表位转录研究的现状，特别是在心肌细胞中。
Similar to DNA modifications, an epitranscriptome of mRNA modifications emerged over the last few years in the cardiovascular system. Specifically, the discovery of the N6-methyladenosine (m6A) as reversible post-transcriptional modification in mRNAs raised recent interest in those modifications in cardiomyocytes and their role in diseased hearts. As mRNA levels of different genes have been shown to not necessarily correspond to respective protein levels, post-transcriptional mRNA modifications have been recognized as a relevant mechanism of gene expression in cardiomyocytes. Consequently, m6A-mRNA methylomes of human cardiac tissue and of animal model heart samples were reported and point toward an important role of m6A modifications in cardiomyocyte cell function. Clearly, additional studies are needed to fully understand this novel stress–response mechanism in the heart for maintaining normal cardiac function. In this chapter, we review the current state of the art of epitranscriptomic research specifically in cardiomyocytes.